NCT01951482View on ClinicalTrials.gov

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Non Squamous Non-small Cell Lung CancerBrain MetastasesBevacizumab
Interventions
DRUG

Pemetrexed/Platinum

pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance every 3 weeks.

DRUG

Bevacizumab and Pemetrexed/platinum

bevacizumab (7.5mg/kg, intravenously on day 1 of each 3-week cycle) plus pemetrexed-platinum chemotherapy (pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle) for four to six cycles, followed by bevacizumab plus pemetrexed maintenance every 3 weeks.

Trial Locations (1)

510060

Sun Yat-sen University of Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT01951482 - Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter